Dr. Welty has over 25 years of experience in pre-clinical and clinical pharmacology leading organizations and project teams from early discovery to approval and commercialization, most recently as the Global Head of DMPK at Shire. He has supported the successful submission of more than 50 IND/CTAs and more than 20 NDA/MAA/BLAs for small molecules, biologics and gene therapy therapeutics. He has extensive experience in pharmacokinetics, pharmacodynamics, systems pharmacology, and model-informed approaches for candidate nomination and efficient clinical development strategy.
His therapeutic area experience includes neurology, ophthalmology for anterior and posterior retinal diseases, and rare disease therapeutics including lysosomal storage diseases, hereditary angioedema, short-bowel syndrome and hemophilia.
We sat down with Devin to learn more about his predicted changes in drug development, favorite projects and therapeutic areas he’s worked on, and his advice for new scientists. Listen to the interview: